How Much Do Peptides Cost in 2026? Real Pricing by Sourcing Path

The honest short answer is that peptide costs depend almost entirely on where you buy. Three sourcing paths produce three very different price points. A peptide-therapy clinic visit typically lands somewhere between $200 and $1,500 per month after consult fees, lab work, and the actual compound. A branded GLP-1 program through a telehealth platform or pharmacy direct-to-consumer site lands roughly between $149 and $349 per month for starter doses, and closer to $349 to $499 per month at maintenance doses. Research-use peptide vials from a grey-market supplier like Peptide Partners are usually priced at a fraction of those per-milligram numbers, but they are sold for research use only and do not include any medical oversight, prescription, or pharmacy fulfillment.

Most published cost guides stop at a single "$200 to $1,500 per month" range and never break it apart. This page goes further: real per-vial prices from Peptide Partners across the most-shopped peptides, current 2026 branded GLP-1 cash-pay pricing from NovoCare and LillyDirect, and the per-milligram gap that drives the value conversation in research-use peptide circles.

The big practical question is not which path is cheapest in the abstract. It is which path matches what someone is actually researching. A person evaluating GLP-1 weight-management options is usually choosing between branded telehealth and compounded telehealth, not research vials. A person already deep in the research-use peptide community comparing Wolverine, GLOW, or BPC-157 prices is usually comparing supplier listings, not clinic packages.

This table puts the cost question on a per-milligram basis so the gap is easier to see. The Peptide Partners column uses buyer-observed research-vial pricing from May 2026. The telehealth column only shows a number when there is a comparable branded or telehealth option on the page; otherwise it is marked N/A.

Two observations worth pulling out. GHK-Cu and NAD+ are the cheapest per milligram by a wide margin because they are sold in larger total-mass brackets. That changes the budget conversation around skin and longevity research compared to peptides priced at $4 to $6 per mg. The Wolverine, GLOW, and KLOW blends look expensive on a sticker basis but their per-mg pricing is competitive because each vial contains multiple compounds, which means one vial covers more research-use ground than buying each piece separately.

Retatrutide is the most-asked GLP cost question on PepPal because there is no FDA-approved branded version yet. Peptide Partners lists Retatrutide research-use vials at brackets between $273 and $1,680, with the largest brackets pricing as low as $3.50 per mg. There is no apples-to-apples branded comparison because Retatrutide is still investigational. For broader context on how Retatrutide fits in the GLP-1, GLP-2, GLP-3 conversation, see how do you get Retatrutide.

Wolverine is the soft-tissue research blend that pairs BPC-157 and TB-500. Peptide Partners lists Wolverine kits between $240 and $920 depending on bracket size, with per-mg pricing around $4.35 to $5.88. Buying the two compounds separately at full per-vial prices usually costs more than buying the blend at a matched total mass. For background on what people are pairing them for, see how do you get the Wolverine stack.

GLOW adds GHK-Cu to the Wolverine concept. Peptide Partners lists GLOW between $225 and $910 across the 140, 350, and 700 mg brackets, with per-mg pricing of roughly $1.30 to $1.60. Because GHK-Cu is the cheapest peptide in the catalog per mg, the GLOW blend prices much more aggressively per mg than the Wolverine blend even though the sticker prices look similar.

KLOW extends GLOW further. Peptide Partners lists KLOW between $264 and $1,080 across the 160, 400, and 800 mg brackets, with per-mg pricing around $1.35 to $1.65. KLOW and GLOW are the cheapest per mg of the named research stacks because they include GHK-Cu by mass.

Standalone BPC-157 lists between $106 and $780 across 20, 50, 100, and 200 mg vials, with per-mg pricing of roughly $3.60 to $4.80. BPC-157 alone is cheaper per mg than buying the BPC-157 / TB-500 combo on a sticker basis, but the combo is cheaper per mg of total active material if both compounds are part of the research plan.

GHK-Cu is the cheapest peptide per mg in the catalog. Peptide Partners lists it between $150 and $900 across 200, 500, 1000, and 2000 mg brackets, with per-mg pricing of roughly $0.45 to $0.75. That is the main reason GHK-Cu shows up in so many community research stacks — the math is friendlier than almost any other compound.

NAD+ is sold in two forms: buffered and unbuffered. Both are listed between $220 and $750 across 1500, 3750, and 7500 mg brackets, with per-mg pricing of roughly $0.10 to $0.15. NAD+ is technically a coenzyme rather than a peptide, but it usually shows up in the same buyer conversation.

MOTs-C lists at two vial-size tiers. The 10 mg vials run $91 to $358 across 20, 50, and 100 mg brackets, with per-mg pricing of $3.58 to $4.55. The 40 mg vials run $252 to $800 across 80, 200, and 400 mg brackets, with per-mg pricing of $2.00 to $3.15. Buyers planning longer research timelines usually go to the larger vial size to drop per-mg cost.

Tirzepatide research-use vials list between $297 and $3,090 across 80, 200, 400, 800, and 1200 mg brackets, with per-mg pricing of $2.58 to $3.71. The branded comparison is below in the GLP-1 section.

Semaglutide research-use vials list between $335 and $1,050 across 50, 100, 150, and 200 mg brackets, with per-mg pricing of $5.25 to $6.70. Stock fluctuates due to ongoing regulatory pressure. For the regulatory backdrop, see the FDA Category 2 fact-check.

This is the comparison most people are actually doing when they Google peptide cost questions. The numbers are not apples-to-apples — branded GLP-1 access includes a prescription, FDA-approved formulation, telehealth visit, and pharmacy fulfillment that research vials do not. Even with that asterisk, the per-mg gap at starter doses is large enough to drive most of the cost-curiosity in this category.

A 0.25 mg per week Wegovy starter plan delivers about 1 mg of semaglutide per month at roughly $199 to $349, which works out to roughly $199 to $349 per milligram of active drug. Peptide Partners research-use semaglutide is listed at roughly $5.25 to $6.70 per milligram. The per-mg gap at the very lowest dose is on the order of 30x to 60x. That gap shrinks at higher branded doses and shrinks again on tirzepatide, because tirzepatide is dosed at higher milligram weights.

Tirzepatide via LillyDirect at the 2.5 mg starter dose comes out to roughly $29.90 per milligram, while research-use tirzepatide lists at roughly $2.58 to $3.71 per milligram. The gap at the starter dose is roughly 8x to 12x. At the 5 mg dose the math compresses to a 5x to 8x gap, and at maintenance doses the gap compresses further.

Clinic pricing usually lands in the $200 to $1,500 per month range and almost never breaks out cost-per-mg. The reason is that the clinic is selling a service bundle, not just a compound. The bundle typically includes the parts below.

The actual compound is usually a small fraction of the total clinic invoice. That is why the same molecule can be priced at $4 per milligram at a research-use supplier and effectively $50 to $200 per milligram inside a clinic package. None of that overhead is wasted — it is what people pay for when they want medical oversight. It is also why the per-mg math gets so skewed when comparing paths.

Buyer-side price differences come down to a few factors. Understanding them makes it easier to compare listings without falling for sticker traps.

Pricing moves quickly in this category. Wegovy and Zepbound cash-pay pricing changed multiple times across late 2025 and early 2026, telehealth platforms restructured their compounded GLP-1 programs after the Hims and Novo settlement, and Peptide Partners catalog stock has changed across some compounds in the last several weeks. Treat every number on this page as a snapshot, not a promise.